Skip to main navigation Skip to search Skip to main content

Differential Expression of RAD51AP1 in Ovarian Cancer: Effects of siRNA In Vitro

  • Alice Filipe
  • , Periklis Katopodis
  • , Dimple Chudasama
  • , Rachel Kerslake
  • , Jeyarooban Jeyaneethi
  • , Vladimir Anikin
  • , Elisabete Silva
  • , Ioannis Kyrou
  • , Harpal S. Randeva
  • , Cristina Sisu
  • , Marcia Hall
  • , Emmanouil Karteris
    • Brunel University
    • Harefield Hospital
    • Sechenov First Moscow State Medical University
    • University Hospitals Coventry and Warwickshire NHS Trust
    • University of Warwick
    • Aston Medical School
    • Agricultural University of Athens
    • Mount Vernon Cancer Centre

    Research output: Contribution to journalArticlepeer-review

    123 Downloads (Pure)

    Abstract

    Background: DNA double strand breaks can affect genome integrity potentially leading to cancer. RAD51-associated protein 1 (RAD51AP1), an accessory protein to RAD51, is critical for homologous recombination, a key DNA damage response pathway. Emerging studies indicate a novel role for RAD51AP1 in carcinogenesis. Here we provide additional insight into the role of RAD51AP1 in ovarian cancer (OvCa). Methods: Gene expression and patient phenotype data were obtained from TCGA and GTEX project consortia for bioinformatics analysis. Immunohistochemistry of OvCa tissue microarray was undertaken. Functional analyses were performed in a SKOV3 OvCa cell line with down-regulation of RAD51AP1 using siRNA. Results: RAD51AP1 is overexpressed at gene level in primary and recurrent OvCa compared to controls. At protein level, RAD51AP1 was up-regulated in low grade serous tumors compared to high grade OvCa. There was higher expression of RAD51AP1 in OvCa metastatic to lymph nodes compared to primary cancer samples. Gene enrichment analyses identified 12 differentially expressed genes (DEGs) related to OvCa, eight of which are also common in tissue from patients with type 2 diabetes mellitus (T2DM). Conclusions: RAD51AP1 is overexpressed in OvCa, Given the link between OvCa and T2DM, the eight-gene signature shows potential for predictive value.

    Original languageEnglish
    Article number201
    Number of pages13
    JournalJournal of Personalized Medicine
    Volume12
    Issue number2
    DOIs
    Publication statusPublished - 1 Feb 2022

    Bibliographical note

    Copyright: © 2022 by the authors.
    Licensee MDPI, Basel, Switzerland.
    This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)

    Funder

    This research was funded by Royal Brompton and Harefield Hospitals Charity, Cancer Treatment and Research Trust (CTRT), University Hospitals Coventry and Warwickshire NHS Trust and Inman Charity.

    Publisher Copyright:
    © 2022 by the authors. Licensee MDPI, Basel, Switzerland.

    Funding

    Funding: This research was funded by Royal Brompton and Harefield Hospitals Charity, Cancer Treatment and Research Trust (CTRT), University Hospitals Coventry and Warwickshire NHS Trust and Inman Charity.

    Funders
    Royal Brompton and Harefield Hospitals Charity
    Cancer Treatment and Research Trust
    University Hospitals Coventry and Warwickshire NHS Trust
    Inman Charity

      UN SDGs

      This output contributes to the following UN Sustainable Development Goals (SDGs)

      1. SDG 3 - Good Health and Well-being
        SDG 3 Good Health and Well-being

      Keywords

      • Biomarker
      • Ovarian cancer
      • RAD51AP1
      • T2DM

      ASJC Scopus subject areas

      • Medicine (miscellaneous)

      Fingerprint

      Dive into the research topics of 'Differential Expression of RAD51AP1 in Ovarian Cancer: Effects of siRNA In Vitro'. Together they form a unique fingerprint.

      Cite this